vimarsana.com

Latest Breaking News On - Neximmune inc - Page 8 : vimarsana.com

NexImmune, Yale, and JDRF Extend Research Partnership for Type 1 Diabetes

A JDRF funded grant is being used to explore the combination of NexImmune’s antigen specific nanoparticles and an anti-CD3 mAb for prevention and treatment of type 1 diabetes GAITHERSBURG, Md.,.

Chad
United-states
Kristi-jones
Kevan-herold
Facebook
Neximmune-inc
Exchange-commission
Instagram
Nasdaq
Chief-executive-officer
Artificial-immune-modulation
Private-securities-litigation-reform-act

NexImmune Announces Presentations at The Society for Immunotherapy of Cancer's 38th Annual Meeting

NexImmune Announces Presentations at The Society for Immunotherapy of Cancer's 38th Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San-diego
California
United-states
Chad
Bryan-hahn
Rui-wang
Lauren-suarez
Jack-ragheb
Durgadas-cherukaraveedu
Sojung-kim
Brian-alvarez
Haiyun-liu

NexImmune (NEXI) Announces 1-for-25 Reverse Stock Split

NexImmune (NEXI) Announces 1-for-25 Reverse Stock Split
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Computershare-trust-company
Nasdaq
Neximmune-inc
Nasdaq-capital-market
Nasdaq-capital

NexImmune Announces 1-for-25 Reverse Stock Split

NexImmune Announces 1-for-25 Reverse Stock Split
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Chad
Computershare-trust-company
Exchange-commission
Nasdaq
Neximmune-inc
Nasdaq-capital-market
Nasdaq-capital
Artificial-immune-modulation
Private-securities-litigation-reform-act
Annual-report

NexImmune, Inc. (NASDAQ:NEXI) Sees Significant Increase in Short Interest

NexImmune, Inc. (NASDAQ:NEXI – Get Free Report) was the recipient of a significant growth in short interest in the month of September. As of September 30th, there was short interest totalling 134,900 shares, a growth of 21.3% from the September 15th total of 111,200 shares. Based on an average daily volume of 83,300 shares, the […]

Nasdaq
Neximmune-inc
Raymond-james-associates
Renaissance-technologies
Vanguard-group-inc
Sei-investments-co
Get-free-report
Street-corp
Vanguard-group
Artificial-immune-modulation
Neximmune-daily

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.